After the second dose, both the Pfizer and AstraZeneca vaccines were said to be almost as effective toward symptomatic disease caused by the Indian variant as they are against the Kent variant.
According to the Public Health England (PHE) report, they were only 33% impactful three weeks after the first dose.
Matt Hancock, the Secretary of State for Health, termed the outcome “groundbreaking,” and the Public Health England said it anticipates even greater levels of efficiency in the battle against hospitalisations and deaths.
The study, which did take place between April 5 and May 16, discovered that two weeks after the second dose, the Pfizer vaccine was 88 percent effective against symptomatic disease caused by the Indian variant, particularly in comparison to 93 percent effectiveness against the Kent variant.
The study included 12,675 genome-sequenced cases, but only 1,054 were of the Indian variant.
The study gathered data from across all age groups getting started on April 5 to make up for the time since the variant was uncovered.
However, according to PHE data, at least 2,889 cases of the Indian variant were confirmed in England between February 1 and May 18.
A total of 104 cases prompted a visit to a hospital emergency department, 31 cases compelled an overnight hospital stay, and six cases led to loss of life.
As per the data, the Kent variant is the most common in England, with 132,082 cases recorded during the same time period.
A total of 1,569 people have died as a direct result of the variant, with 2,011 cases requiring an overnight stay in the hospital and 5,238 requesting a visit to the hospital emergency room.